supp.fit

Idebenone: study protocols

21 study groups say how much Idebenone participants took a day. These are the doses the studies gave. They are not a recommendation.

Idebenone: what the research found →

Dose per serving from research

18 study groups in 14 studies say how much Idebenone participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg, 44% of 18 study groups.

Daily doseStudy groups
50 mg or less
1
50 mg to 100 mg
3
100 mg to 250 mg
0
250 mg to 500 mg
8
500 mg to 1 g
6

Commonly used together

None of these 21 study groups took Idebenone with anything else.

21 study groups

Study
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
2016 · idebenone group · Patients aged 10–18 years with Duchenne muscular dystrophy who were not taking concomitant glucocorticoid steroids
900 mg1 year31
Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
1998 · placebo for 12 months, followed by idebenone 90 mg tid for another 12 months · Patients with mild to moderate dementia of the Alzheimer type
270 mg1 year153
Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
1998 · idebenone 120 mg tid for 24 months · Patients with mild to moderate dementia of the Alzheimer type
360 mg2 years149
Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
1998 · idebenone 90 mg tid for 24 months · Patients with mild to moderate dementia of the Alzheimer type
270 mg2 years148
Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study
2002 · idebenone · Men and women aged 40–90 with mild-to-moderate dementia of the Alzheimer type
360 mg60 weeks104
A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
1997 · idebenone 30 mg t.i.d. · Patients with mild to moderate dementia of the Alzheimer type
90 mg26 weeks100
A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
1997 · idebenone 90 mg t.i.d. · Patients with mild to moderate dementia of the Alzheimer type
270 mg26 weeks100
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy
2011 · Idebenone 900 mg/day · People aged 14–64 with Leber's hereditary optic neuropathy and one of the specified mitochondrial DNA mutations, with vision loss onset within 5 years; both sexes
900 mg24 weeks55
Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial
1992 · idebenone · Patients with mild-to-moderate multi-infarct dementia
90 mg90 days52
Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial
1992 · idebenone · elderly patients with senile cognitive decline
90 mg—39
Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
2015 · idebenone · Patients aged 10–18 years with Duchenne muscular dystrophy who were not taking concomitant glucocorticoids
900 mg52 weeks32
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy
2017 · Idebenone · Patients aged 10–18 years with Duchenne muscular dystrophy, PEF percent predicted below 80%, and no glucocorticoid use during the study
900 mg52 weeks31
Home-Based Monitoring of Pulmonary Function in Patients with Duchenne Muscular Dystroph
2018 · Idebenone · Patients aged 10–18 years with Duchenne muscular dystrophy and pulmonary function decline (PEF% predicted ≤80%); off glucocorticoids for at least 1 year before enrolment
900 mg52 weeks31
Effects of idebenone on color vision in patients with leber hereditary optic neuropathy
2013 · idebenone · Patients with Leber hereditary optic neuropathy (LHON) caused by one of three primary mtDNA mutations, with vision loss within 5 years before enrolment; age range and sex not restricted
900 mg24 weeks28
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial
2011 · idebenone · Children aged 8–16 years with Duchenne muscular dystrophy
450 mg1 year13
Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
1992 · idebenone · Elderly patients with mild to moderate mental deterioration of vascular origin (multi-infarct dementia)
45 mg120 days—
Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy
2013 · Idebenone, glucocorticoid-naïve patients · Boys aged 8–16 years with Duchenne muscular dystrophy who were glucocorticoid-naïve
450 mg1 year—
Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy
2013 · Idebenone, patients receiving concomitant glucocorticoids · Boys aged 8–16 years with Duchenne muscular dystrophy receiving concomitant glucocorticoids
450 mg1 year—
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
2007 · approximately 5 mg/kg idebenone group · Patients aged 9–17 years with genetically confirmed Friedreich's ataxia
5 mg/kg26 weeks—
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
2007 · approximately 15 mg/kg idebenone group · Patients aged 9–17 years with genetically confirmed Friedreich's ataxia
15 mg/kg26 weeks—
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
2007 · approximately 45 mg/kg idebenone group · Patients aged 9–17 years with genetically confirmed Friedreich's ataxia
45 mg/kg26 weeks—